4-phenylazo-benzoic acid methylamide | 102840-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: 4-phenylazo-benzoic acid methylamide
• 英文别名: 4-Phenylazo-benzoesaeure-methylamid
• CAS: 102840-84-6
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: VGPPWQFFLUAKHY-WUKNDPDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.46
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  53.82
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  4-苯基偶氮苯甲酰氯 、 甲胺 生成 4-phenylazo-benzoic acid methylamide
  参考文献：
  名称：

  p-Phenylazobenzoyl Chloride for Identification and Chromatographic Separation of Colorless Compounds. II. Amines¹

  摘要：

  DOI：

  10.1021/jo01110a016

文献信息

• [EN] METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES<br/>[FR] PROCEDE POUR PREPARER DE NOUVEAUX ANALOGUES DE NUCLEOSIDE, ET LEURS UTILISATIONS
  申请人：AUSPEX PHARMACEUTICALS INC

  公开号：WO2005049582A1

  公开（公告）日：2005-06-02

  Processes for the preparation of racemic and optically active nucleoside analogs of formula (A) are described. These compounds are useful as anti-infective agents, antisense therapeutic agents and hybridization assay probes.

  描述了制备式(A)的外消旋和光学活性核苷类似物的过程。这些化合物可用作抗感染剂、反义治疗剂和杂交分析探针。
• MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Jandeleit Bernd

  公开号：US20090069419A1

  公开（公告）日：2009-03-12

  Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

  掩蔽羧酸新戊磺酰酯丙戊酸酯前药，包含此类前药的药物组合物，以及使用此类前药和组合物治疗疾病的方法被披露。具体来说，披露了表现出增强口服生物利用度的丙戊酸酯前药和使用丙戊酸酯前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化症和疼痛的方法。
• Diastereoselective hydrogenation of 1,3-hydroxyketones
  申请人：——

  公开号：US20040010154A1

  公开（公告）日：2004-01-15

  The invention relates to a novel process of diastereoselective hydrogenation of 1,3-hydroxyketones of formula (I) 1 wherein R, R′ and R″ are as defined in claim 1 which is carried out in a solvent in the presence of a magnesium salt, a heterogeneous platinum catalyst and optionally an oxidant.

  这项发明涉及一种新型的对1,3-羟基酮进行不对映选择性加氢的方法，其化学式为(I)，其中R、R'和R''如权利要求1所定义，在溶剂中，在存在镁盐、非均相铂催化剂和可选氧化剂的情况下进行。
• PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST
  申请人：Komiyama Masato

  公开号：US20110313169A1

  公开（公告）日：2011-12-22

  A process for efficiently producing, through few steps either a xanthine oxidase inhibitor, which is a therapeutic agent for hyperuricemia, or an intermediate therefore. The process is a novel coupling process which comprises subjecting a compound represented by formula (1) to coupling reaction with a compound represented by formula (2) in the presence of a transition metal compound to thereby obtain a compound represented by formula (3).

  一种高效生产黄嘌呤氧化酶抑制剂或其中间体的方法，该抑制剂是治疗高尿酸血症的药物。该方法是一种新型偶联过程，包括将式（1）表示的化合物与式（2）表示的化合物在过渡金属化合物存在下进行偶联反应，从而获得式（3）表示的化合物。
• [EN] SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] INHIBITEURS PROLINE SUBSTITUÉE DE RÉPLICATION DU VIRUS DE L'HÉPATITE C
  申请人：INTERMUNE INC

  公开号：WO2012040242A1

  公开（公告）日：2012-03-29

  The embodiments provide compounds of the general Formulae I, la, II,IIa,III, IIIa, Illb, IV, IVa, IVb, V, Va, Vb, VI, VIa, VIb, and VIc, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. The embodiments also provide methods for the synthesis of subject compounds and intermediates in the synthetic methods.

  该实施例提供了一般式I、Ia、II、IIa、III、IIIa、IIIb、IV、IVa、IVb、V、Va、Vb、VI、VIa、VIb和VIc的化合物，以及包括药物化合物的组合物，包括制药组合物。该实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用所述化合物或组合物的有效量。该实施例还提供了用于合成所述化合物和合成方法中间体的方法。